Our team

Antoine started his career as a Research Scientist in oncology at Sanofi then spent 20 years in Technology Transfer Offices and as an adviser and business developer for biotech companies.

Antoine holds an engineering degree in biology combined with an MBA.

Hatem is a seasoned drug developer with more than 20 years of healthcare and biotech or pharmaceutical industry experience, having led the advancement of about fifteen of early to late-stage clinical drug development programs in oncology.

Before joining PEP-Therapy, Hatem was Chief Medical Officer at Emergence Therapeutics (acquired by Eli Lilly), Head of early clinical development at Pierre Fabre and Vice President, Head of clinical development at Innate Pharma.

Hatem has also held several academic appointments including Medical Oncologist and Scientific Director at the Jules Bordet Institute in Brussels, Belgium and Adjunct Assistant Professor of Oncology at the American University of Beirut, Lebanon. He is still acting as a senior faculty at the college of the European School of Oncology and a consultant at the Cairo Cure Oncology Center, Egypt.

Hatem is highly published with more than 140 research papers and 10 book chapters. Hatem has served as member of several international guideline committees and has been invited as faculty member on numerous occasions including at the annual conferences of the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO). He is the recipient of several awards, including the ASCO Merit Award and the ESMO Translational Research Award.

Before joining PEP-Therapy, Diego pursued post-doctoral research at Gustave Roussy Institute focusing on Oncology and HIV. He then joined Oregon Therapeutics, a biotechnology company, as Senior Scientist working on preclinical research in Oncology. He has 13 years experience in research fields including Oncology, Virology and Molecular Biology.
He holds a Master degree in Health Biotechnology and a PhD in Microbiology and Virology .